Diagnostic approach and role of MRI in the assessment of acute myocarditis

Cardiology in Review

Volumn 17, Issue 1, 2009, Pages 24-30

  Nelson, Katarina H ^a   Li, Tao ^b   Afonso, Luis ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Acute myocarditis; Cardiac MRI; Diagnostic techniques; Gold standard

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIDOL; GALLIUM CITRATE GA 67; MYOSIN ANTIBODY IN 111; TROPONIN I; TROPONIN T; DIAGNOSTIC AGENT; GADOLINIUM;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; ACUTE MYOCARDITIS; CINEANGIOCARDIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ECHOCARDIOGRAPHY; FUNCTIONAL ASSESSMENT; HEART FUNCTION TEST; HEART MUSCLE BIOPSY; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MYOCARDITIS; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIOCARDIOGRAPHY; REVIEW; TISSUE DOPPLER IMAGING; VIRUS MYOCARDITIS;

ACUTE DISEASE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDITIS;

EID: 59849104098     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318184b383     Document Type: Review

References (51)

1. Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart. 2006;92:316-320.
2. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113:876-890.
3. Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 1998;97:1802-1809.
4. Roditi GH, Hartnell GG, Cohen MC. MRI changes in myocarditis-evaluation with spin echo, cine MR angiography and contrast enhanced spin echo imaging. Clin Radiol. 2000;55:752-758.
5. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immuno-suppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269-275.
6. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopatho-logic definition and classification. Am J Cardiovasc Pathol. 1987;1:3-14.
7. Abelmann WH, Baim DS, Schnitt SJ. Endomyocardial biopsy: is it of clinical value? Postgrad Med J. 1992;68(Suppl 1):S44-S46.
8. Wu LA, Lapeyre AC III, Cooper LT. Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis. Mayo Clin Proc. 2001;76:1030-1038.
9. Laissy JP, Hyafil F, Feldman LJ, et al. Differentiating acute myocardial infarction from myocarditis: diagnostic value of early- and delayed-perfusion cardiac MR imaging. Radiology. 2005;237:75-82.
10. Cooper LT Jr. Giant cell myocarditis: diagnosis and treatment. Herz. 2000; 25:291-298.
11. Shonk JR, Vogel-Claussen J, Halushka MK, et al. Giant cell myocarditis depicted by cardiac magnetic resonance imaging. J Comput Assist Tomogr. 2005;29:742-744.
12. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007;28:1326-1333.
13. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914-1931.
14. Lauer B, Niederau C, Kuhl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997;30:1354 -1359.
15. Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation. 1997;95:163-168.
16. Pinamonti B, Alberti E, Cigalotto A, et al. Echocardiographic findings in myocarditis. Am J Cardiol. 1988;62:285-291.
17. Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45:1815-1822.
18. Thuny F, Avierinos JF, Jop B, et al. Images in cardiovascular medicine. Massive biventricular thrombosis as a consequence of myocarditis: findings from 2-dimensional and real-time 3-dimensional echocardiography. Circulation. 2006;113:e932-e933.
19. Skouri HN, Dec GW, Friedrich MG, et al. Noninvasive imaging in myocarditis. J Am Coll Cardiol. 2006;48:2085-2093.
20. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114:1883-1891.
21. Yasuda T, Palacios IF, Dec GW, et al. Indium 111-monoclonal antimyosin antibody imaging in the diagnosis of acute myocarditis. Circulation. 1987; 76:306-311.
22. Dec GW, Palacios I, Yasuda T, et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol. 1990;16:97-104.
23. Margari ZJ, Anastasiou-Nana MI, Terrovitis J, et al. Indium-111 monoclonal antimyosin cardiac scintigraphy in suspected acute myocarditis: evolution and diagnostic impact. Int J Cardiol. 2003;90:239 -245.
24. Lekakis J, Nanas J, Moustafellou A, et al. Antimyosin scintigraphy for detection of myocarditis. Scintigraphic follow-up. Chest. 1993;104:1427- 1430.
25. Narula J, Khaw BA, Dec GW, et al. Diagnostic accuracy of antimyosin scintigraphy in suspected myocarditis. J Nucl Cardiol. 1996;3:371-381.
26. O'Connell JB, Fowles RE, Robinson JA, et al. Clinical and pathologic findings of myocarditis in two families with dilated cardiomyopathy. Am Heart J. 1984;107:127-135.
27. Reznick JW, Braunstein DB, Walsh RL, et al. Lyme carditis. Electrophysi-ologic and histopathologic study. Am J Med. 1986;81:923-927.
28. Matsuura H, Ishikita T, Yamamoto S, et al. Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease (mucocutaneous lymph node syndrome): the usefulness of single photon emission computed tomography. Br Heart J. 1987;58:385-392.
29. O'Connell JB, Henkin RE, Robinson JA, et al. Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy-proven myocarditis. Circu lation. 1984;70:58-62.
30. Liu PP, Yan AT. Cardiovascular magnetic resonance for the diagnosis of acute myocarditis: prospects for detecting myocardial inflammation. J Am Coll Cardiol. 2005;45:1823-1825.
31. Laissy JP, Messin B, Varenne O, et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest. 2002; 122:1638-1648.
32. Zagrosek A, Wassmuth R, Abdel-Aty H, et al. Relation between myocardial edema and myocardial mass during the acute and convalescent phase of myocarditis-a CMR study. J Cardiovasc Magn Reson. 2008;10:19.
33. Schulz-Menger J, Wassmuth R, Abdel-Aty H, et al. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart. 2006;92:399-400.
34. Abdel-Aty H, Simonetti O, Friedrich MG. T2-weighted cardiovascular magnetic resonance imaging. J Magn Reson Imaging. 2007;26:452-459.
35. De Cobelli F, Pieroni M, Esposito A, et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol. 2006;47: 1649-1654.
36. Gutberlet M, Spors B, Thoma T, et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology. 2008;246:401-409.
37. Abdel-Aty H, Zagrosek A, Schulz-Menger J, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation. 2004;109:2411-2416.
38. Sechtem U, Mahrholdt H, Vogelsberg H. Cardiac magnetic resonance in myocardial disease. Heart. 2007;93:1520-1527.
39. Bohl S, Wassmuth R, Abdel-Aty H, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging. 2008;24:597-607.
40. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250-1258.
41. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myo-cardial damage, and clinical course of viral myocarditis. Circulation. 2006; 114:1581-1590.
42. Wagner A, Schulz-Menger J, Dietz R, et al. Long-term follow-up of patients with acute myocarditis by magnetic resonance imaging. MAGMA. 2003;16: 17-20.
43. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006; 48:1977-1985.
44. Kramer CM, Budoff MJ, Fayad ZA, et al. ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol. 2007;50: 1097-1114.
45. Mitchell JH, Hadden TB, Wilson JM, et al. Clinical features and usefulness of cardiac magnetic resonance imaging in assessing myocardial viability and prognosis in Takotsubo cardiomyopathy (transient left ventricular apical ballooning syndrome). Am J Cardiol. 2007;100:296-301.
46. Abdel-Aty H, Cocker M, Friedrich MG. Myocardial edema is a feature of Tako-Tsubo cardiomyopathy and is related to the severity of systolic dysfunction: insights from T2-weighted cardiovascular magnetic resonance. Int J Cardiol. In press.
47. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging. 2007;7:130-137.
48. Thomsen HS. Imaging patients with chronic kidney disease: CIN or NSF? Radiol Med (Torino). 2007;112:621-625.
49. Saxena SK, Sharma M, Patel M, et al. Nephrogenic systemic fibrosis: an emerging entity. Int Urol Nephrol. 2008;40:715-724.
50. Shamsi K, Yucel EK, Chamberlin P. A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol. 2006;41:822-830.
51. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens. 2008;17:315-319.